A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
about
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese populationCD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approachCyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) studyGenetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer riskAssociation of polymorphisms of PTGS2 and CYP8A1 with myocardial infarctionCYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) studyHuman-specific derived alleles of CD33 and other genes protect against postreproductive cognitive declineCyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.Use of genetic data to guide therapy in arterial disease.The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies.Influence of age and gender on association between -765G > C COX-2 genetic polymorphism and gastric adenocarcinoma risk: a case-control study in Iran.-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.Analysis of interleukin-8 gene variants reveals their relative importance as genetic susceptibility factors for chronic periodontitis in the Han populationRole of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.No association of nineteen COX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study.Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinomaTreatment outcome of chronic low back pain and radiographic lumbar disc degeneration are associated with inflammatory and matrix degrading gene variants: a prospective genetic association study.Genes and abdominal aortic aneurysm.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.PharmGKB summary: very important pharmacogene information for PTGS2.Intermediate phenotypes in schizophrenia: a selective review.The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 geneAssociation of cyclooxygenase-2 genetic variant with cardiovascular disease.Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.Association of COX-2 -765G>C genetic polymorphism with coronary artery disease: a meta-analysis.Disturbance of vision by COX-2 inhibitors.Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1).Pharmacogenetics of analgesic drugsPriorities and standards in pharmacogenetic research.Linkage of large-vessel carotid atherosclerotic stroke to inflammatory genes via a systematic screenThe pharmacogenetic impact of inflammatory genes on bladder cancer recurrence.Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics.Genetics of inflammation in age-related atherosclerosis: its relevance to pharmacogenomics.Molecular genetics of myocardial infarctionCyclooxygenase products and atherosclerosis
P2860
Q24297364-179C2783-0413-4E99-A484-9B5CCD574744Q24634132-29D313DE-1BB1-47A8-A443-CC7FB73CB833Q24645957-FAA31B97-5434-424F-9510-030E927D21D9Q25255846-079C5EA3-631C-4E0B-9564-2DF78EF1F4DFQ25257445-5042FE2F-018D-4A94-AC86-EEF348118C30Q28199903-C562752D-9C43-4D52-9A71-7B0667D3B3A6Q28210322-02606079-AB73-4274-A771-B3DB9B30E0BBQ28213217-EF739805-717D-4B72-9A57-077327108B9CQ28239543-606F30A0-B71F-4E1C-A3C6-79210AC92E4BQ28396513-9F39D733-89B0-4CA3-9117-4A054BFF0E3BQ28602637-2530FC8F-E5EE-441F-B66F-A44C5CC58365Q30494961-FB7F0F5D-7977-4C63-B21E-ED58AE63E3CCQ30978916-23C0A521-54C3-416D-9618-41C7954FB51FQ33440652-07A29F16-E9B8-4A43-9017-B84F3C4D7664Q33596371-80CF3B83-6778-4922-9C56-B5FD343B8F94Q33869492-C18DA714-0CDA-4386-AD06-9BC24A50E1C0Q34015742-42FE6E2B-EA6B-4301-8B8C-42EAF397D00CQ34096844-94E84E65-72A6-4564-A192-49F907F63BDCQ34253730-01B01E9D-5D70-46F8-891B-8F8B0079A589Q34430932-720B3FF6-81CD-4A95-A1AD-4859B59F6654Q34632871-6A454BF8-8CFE-4B47-8002-A70EEF008217Q34683905-3517A842-8543-440C-AAFD-76E7815BEB6FQ34771381-429D9D91-A61A-4D45-B8DC-77EF0F0D82BEQ35120350-2B495F35-E4DB-4F8B-9FD4-6DF076594BF7Q35236607-3F97BBD0-73E8-4BB7-BCD8-CA71F79F35F7Q35373720-C64432CF-3D13-47C4-BC5B-AF79ABCFFA13Q35608507-650381C5-008F-45ED-A4C5-D4A4DF1F4D53Q35827780-D5240646-4F53-4B27-946B-3B0B068646C1Q35870790-D1392289-382C-485A-A6E1-3DBC93AF1735Q35925659-BB790BA2-E893-4031-9D74-6AB91B829AA1Q35976402-78BC1B3B-AABB-4CCE-BF03-5FFD3FBC77A2Q36091906-47DC890A-62F9-4603-89C9-7DE9381A341FQ36110592-3CD957AD-D476-477A-A1F2-632C8E2095B1Q36180606-EFE8CE13-4B8A-47F7-89E1-FAA6E483DF0EQ36222086-E6E3D66D-F15F-476B-874B-0EB2283C77E9Q36249221-C3AF299A-C3B3-460C-A9F8-E986DA298D2FQ36402212-C9969DD4-B7B0-48F0-BD77-E1F87E5F887FQ36802131-D57838A1-3DF0-45C1-B7E9-4B0A13D4CCB7Q36843011-DD1120F1-FDC5-4951-AA5D-45C6DD457F23Q37071164-04276C2F-4DBE-4A42-A4ED-2431A4D2F609
P2860
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@en
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@nl
type
label
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@en
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@nl
prefLabel
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@en
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@nl
P2093
P356
P1476
A polymorphism in the cyclooxy ...... cardial infarction and stroke.
@en
P2093
Agostino Virdis
Alberto Notarbartolo
Andrea Mezzetti
Anna Montali
Annalisa Iezzi
Barbara Pini
Chiara Cuccurullo
Elena Toniato
Filomena Campagna
Francesco Spigonardo
P304
P356
10.1001/JAMA.291.18.2221
P407
P577
2004-05-01T00:00:00Z